Jefferies upgraded Grifols, S.A. from Hold to Buy
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/12/2025 | Overweight | Morgan Stanley | |
| 3/12/2024 | Hold → Sell | Deutsche Bank | |
| 4/12/2023 | Equal-Weight → Overweight | Morgan Stanley | |
| 3/3/2023 | Overweight → Equal-Weight | Morgan Stanley | |
| 2/16/2023 | Underweight → Equal Weight | Barclays | |
| 1/18/2023 | Hold → Buy | Jefferies | |
| 4/8/2022 | Equal-Weight | Morgan Stanley | |
| 11/5/2021 | Buy → Hold | Deutsche Bank |
6-K - Grifols SA (0001438569) (Filer)
6-K - Grifols SA (0001438569) (Filer)
SCHEDULE 13G/A - Grifols SA (0001438569) (Subject)
Chronos‑PD shows that biological changes associated with Parkinson's disease (PD) can emerge up to 12 years before clinical diagnosisUncovered reproducible early molecular signals and distinct molecular patterns in PD, supporting future efforts in patient stratification and precision medicine researchChronos is part of a broad Grifols program to find early disease biomarkers leveraging more than 100 million proprietary plasma samples connected to real-world data on thousands of conditions Grifols presents data in 13 posters and oral presentations at AD/PD™ 2026 conference in Copenhagen (Denmark) BARCELONA, Spain, March 17, 2026 (GLOBE NEWSWIRE) -- Grifols ((MCE:GRF, MCE:GRF.P, NASDAQ:GRFS
Believes Board Leadership Continuity and Continued Management Focus and Execution Will Drive Long-Term Shareholder Value Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 3% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today announced that it sent a letter to the Grifols Board of Directors (the "Board") expressing Mason's support for the Company's recommended slate of director candidates for election at the Ordinary General Shareholders' Meeting to be held on June 4 and 5, 2025. The full text of the letter follows: May 28, 2025 Grifols, S.A. Avinguda de la Generalitat 152-158 0
‘Chronos-PD' is looking for biological signals that could indicate increased chance of developing Parkinson's disease (PD) years before symptoms appear, leading to new diagnostic tools and disease-modifying therapiesPart of broad Grifols program to find disease-revealing clues in more than 100 million proprietary plasma samples connected to real-world data on thousands of disease states in many therapeutic areasCutting-edge use of AI and proteomics technology paired with real-world evidence underscores the company's ongoing commitment to bold scientific innovation to benefit patients BARCELONA, Spain, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Grifols ((MCE: GRF, MCE: GRF.P, NASDAQ:GRFS), a global
Morgan Stanley resumed coverage of Grifols, S.A. with a rating of Overweight
Deutsche Bank downgraded Grifols, S.A. from Hold to Sell
Morgan Stanley upgraded Grifols, S.A. from Equal-Weight to Overweight
BARCELONA, Spain, Jan. 4, 2022 /PRNewswire/ -- Grifols ((MCE: GRF, MCE: GRF.P, NASDAQ:GRFS), a global healthcare company and one of world's top producers of plasma-derived medicines, today announced the acquisition of its first donation center in Canada as part of the company's commitment to increase the availability of lifesaving plasma medicines in the country. In a share-purchase agreement, Grifols Canada Therapeutics Inc has acquired Prometic Plasma Resources Inc's (PPR) donation center in Winnipeg from Kedrion for USD 4 million in cash. With the center, Grifols furthers
Sends Letter to Board Detailing Board's Conflicts of Interest and History of Poor Capital Allocation Expresses Urgent Need for Independent Directors and Proper Oversight to Unlock Value Believes Rumored Brookfield Transaction Substantially Undervalues Grifols Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the "Board"). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241107873955/en/Historical Forward EV/EBITDA Multip
BARCELONA, Spain, April 18, 2023 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people's health and well-being for more than 110 years, today announces the filling of its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the United States Securities and Exchange Commission ("SEC"). Grifols' annual report under Form 20-F is a critical component of the company's commitment to transparency and accountability. The filing of the annual report provides investors with an overview of the company's governance practices, including informa
Victor Grifols Roura, who devoted 50 years to building Grifols in senior roles including CEO for 30 years, retires as non-executive Chairperson and is designated as Chairperson of Honor in recognition of his numerous contributionsSteven F. Mayer, former Co-Head of Global Private Equity and Chairman of the Investment Committee of private investment firm Cerberus Capital Management, L.P., with more than 10 years serving as a Grifols independent board member, is appointed as Executive ChairpersonChanges further evidence of the Board of Directors' focus on strategic objectives, operational excellence, and deleveraging balance sheetBARCELONA, Spain, Oct. 3, 2022 /PRNewswire/ -- Grifols (MCE: GRF)
SC 13G/A - Grifols SA (0001438569) (Subject)
SC 13G/A - Grifols SA (0001438569) (Subject)
SC 13G - Grifols SA (0001438569) (Subject)